In an era where gene therapy is rapidly reshaping our approach to treating complex diseases, XyloCor Therapeutics, a clinical-stage biopharmaceutical company, is standing at the forefront of innovation. With their groundbreaking gene therapies for cardiovascular disease, they are poised to revolutionize patient care. Now, their ambitious journey has received a significant boost from the global leading independent Private Equity fund, Jeito Capital. In a bold move, Jeito Capital is leading a $67.5 million (€64.4 million) Series B financing round, effectively accelerating the development of XyloCor’s pioneering solutions.
Operating with a patient-centric approach, Jeito Capital has a history of nurturing groundbreaking medical innovations, cultivating market leaders in therapeutic domains. With €534 million in funds under their management, their strategic investments are designed to enhance patient access to novel treatments worldwide, particularly in Europe and the United States. The substantial investment in XyloCor Therapeutics underscores Jeito’s commitment to driving impactful healthcare advancements and their faith in the transformative potential of gene therapy.
The funding will fuel XyloCor’s efforts as they advance one-time gene therapy applications to address critical treatment gaps among under-served patients with cardiovascular disease. The investment will specifically support two randomized, double-blind Phase 2 trials. The first, EXACT-2, is scheduled to launch in 2025. The second will test XC001 as an adjunctive treatment to coronary artery bypass graft surgery (CABG), a procedure typically recommended when significant blockages in the major coronary arteries demand intervention. XC001’s role in this context is to promote the growth of new blood vessels in areas of the heart not treated by bypass grafts, potentially enhancing the procedure’s overall success and patient outcomes.
The collaboration between Jeito Capital and XyloCor Therapeutics signifies more than a financial investment; it symbolizes a strategic alliance that is poised to drive innovation and improve patient outcomes in the realm of cardiovascular health. The alliance also reflects a broader industry trend towards harnessing the transformative potential of gene therapy to address a wide range of complex diseases.
As Rachel Mears, Partner at Jeito Capital, prepares to join XyloCor’s Board of Directors, the future looks promising for the advancement of XyloCor’s novel gene therapies. This partnership is a testament to the power of collaborative efforts in the biotech industry, where shared vision and strategic alliances can pave the way for groundbreaking healthcare advancements. With this significant backing, XyloCor is set to make waves in cardiovascular disease treatment, potentially reshaping the future of patient care.
Read more from finanznachrichten.de
